Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
A federal judge in Maryland ruled that Hoffman-La Roche (RHHBY) must respond to whistleblower allegations of falsifying claims regarding Tamiflu's effectiveness and inducing the government to stockpile the drug. The lawsuit, filed under the False Claims Act, could lead to penalties exceeding $4 billion due to Roche's alleged misleading claims that influenced government purchases. Despite warnings from the FDA about unsupported claims, Roche received over $1.4 billion from the government between 2005 and 2009 for Tamiflu stockpiles. The case highlights the importance of safeguarding taxpayer interests against corporate fraud.
Roche's press release highlights promising 2-year data from the FIREFISH study of Evrysdi for treating spinal muscular atrophy (SMA) in infants. At the 2-year mark, 88% of infants treated were alive and did not require permanent ventilation. Additionally, 59% could sit unsupported for at least 5 seconds. There were no new safety concerns identified. Earlier, the FDA approved Evrysdi for SMA in patients aged 2 months and older. Roche remains optimistic about the ongoing assessments of survival and motor function for this innovative treatment.